BiotechTubeBiotechTube
Home/Curis/Robert Martell, M.D., Ph.D.
RM

Robert Martell, M.D., Ph.D.

Chief Scientific Officer

Curis

Therapeutic Areas

OncologyHematologic MalignanciesSolid Tumors

Curis Pipeline

DrugIndicationPhase
Emavusertib (CA-4948)IRAK4-driven Leukemia (AML/MDS)Phase 1/2
Fimepinostat (CUDC-907)MYC-altered Cancers (DLBCL, solid tumors)Phase 2
Fimepinostat + VenetoclaxDLBCL (including double-hit lymphoma/HGBL)Phase 1
CA-170PD-L1/VISTA-expressing Cancers (e.g., Mesothelioma)Phase 1
CA-327PD-L1/TIM3-expressing CancersProof of Principle

Leadership Team at Curis

JD
James Dentzer
President & CEO
DD
Diantha Duvall
Chief Financial Officer
AH
Ahmed Hamdy, MBBCH
Chief Medical Officer
JZ
Jonathan Zung, Ph.D.
Chief Development Officer
NS
Nancy Soohoo
Vice President & General Counsel
ME
Maureen E. Lane, Ph.D.
Vice President, Clinical and Translational Science
NP
Nick Pelletier, MBA
Vice President, Clinical Operations
LZ
Li Zhou, Ph.D.
Vice President, Biostatistics
MN
Mark Noel
Vice President, Technology Management & Intellectual Property
RB
Rachel Blasbalg
Senior Director, Human Resources
View full Curis profile